KHTR.F Stock Overview
Develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for KHTR.F from our risk checks.
My Notes
Capture your thoughts, links and company narrative
Knight Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$4.00 |
| 52 Week High | CA$4.55 |
| 52 Week Low | CA$3.48 |
| Beta | 0.48 |
| 1 Month Change | 6.70% |
| 3 Month Change | 7.94% |
| 1 Year Change | -4.20% |
| 3 Year Change | -7.74% |
| 5 Year Change | -30.11% |
| Change since IPO | -27.78% |
Recent News & Updates
Recent updates
Shareholder Returns
| KHTR.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0.8% | 1.2% | -0.3% |
| 1Y | -4.2% | 1.1% | 20.4% |
Return vs Industry: KHTR.F underperformed the US Pharmaceuticals industry which returned 1.3% over the past year.
Return vs Market: KHTR.F underperformed the US Market which returned 22% over the past year.
Price Volatility
| KHTR.F volatility | |
|---|---|
| KHTR.F Average Weekly Movement | 4.0% |
| Pharmaceuticals Industry Average Movement | 10.4% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 18.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: KHTR.F has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine KHTR.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 725 | Samira Sakhia | www.gud-knight.com |
Knight Therapeutics Inc. develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma. The company provides Ladecvina for multiple myeloma and myelodysplastic syndrome, mantle cell lymphoma, and follicular lymphoma; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Rembre for chronic myeloid leukemia; Palbocil for breast cancer; Ambisome and Cresemba for fungal infection; Impavido for leishmaniasis; Dolufevir for HIV infection; Exelon for dementia; and Ibsrela for irritable bowel syndrome with constipation.
Knight Therapeutics Inc. Fundamentals Summary
| KHTR.F fundamental statistics | |
|---|---|
| Market cap | US$403.82m |
| Earnings (TTM) | -US$21.52m |
| Revenue (TTM) | US$244.13m |
1.6x
P/S Ratio-18.7x
P/E RatioIs KHTR.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KHTR.F income statement (TTM) | |
|---|---|
| Revenue | CA$348.64m |
| Cost of Revenue | CA$180.37m |
| Gross Profit | CA$168.27m |
| Other Expenses | CA$199.00m |
| Earnings | -CA$30.73m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.31 |
| Gross Margin | 48.26% |
| Net Profit Margin | -8.81% |
| Debt/Equity Ratio | 6.7% |
How did KHTR.F perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/07 14:30 |
| End of Day Share Price | 2025/02/07 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Knight Therapeutics Inc. is covered by 16 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Kideckel | Beacon Securities Limited |
| David Martin | Bloom Burton & Co. |
| Tania Armstrong-Whitworth | Canaccord Genuity |